Patents by Inventor Claudia Blümel
Claudia Blümel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11926666Abstract: The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CDS on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: May 3, 2021Date of Patent: March 12, 2024Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Bertram Weiss, Anna-Lena Frisk, Ruprecht Zierz, Peter Kufer, Tobias Raum, Doris Rau, Jonas Anlahr, Ralf Lutterbüse, Lisa Nahrwold, Christoph Dahlhoff, Claudia Blümel, Patrick Hoffmann
-
Patent number: 11884720Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: August 1, 2016Date of Patent: January 30, 2024Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.Inventors: Tobias Raum, Jonas Anlahr, Julie Bailis, Claudia Blümel, Patrick Hoffmann, Peter Kufer, Elisabeth Nahrwold, Doris Rau
-
Publication number: 20230312717Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: December 21, 2022Publication date: October 5, 2023Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
-
Publication number: 20230272113Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human FLT3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: July 19, 2022Publication date: August 31, 2023Inventors: Tobias Raum, Claudia Blümel, Franziska Bott, Christoph Dahlhoff, Patrick Hoffmann, Elisabeth Nahrwold, Jochen Pendzialek
-
Patent number: 11692031Abstract: The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: August 2, 2019Date of Patent: July 4, 2023Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.Inventors: Christoph Dahlhoff, Claudia Blümel, Johannes Brozy, Tobias Raum, Elisabeth Nahrwold, Tara Arvedson, Irwin Chen, Sandra Ross, Julie Bailis
-
Patent number: 11591396Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.Type: GrantFiled: May 6, 2020Date of Patent: February 28, 2023Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
-
Publication number: 20230041876Abstract: The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CDS on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: May 3, 2021Publication date: February 9, 2023Inventors: Bertram Weiss, Ann-Lena Frisk, Ruprecht Zierz, Peter Kufer, Tobias Raum, Doris Rau, Jonas Anlahr, Ralf Lutterbüse, Lisa Nahrwold, Christoph Dahlhoff, Claudia Blümel, Patrick Hoffmann
-
Publication number: 20220403037Abstract: The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: June 2, 2022Publication date: December 22, 2022Inventors: NATHAN WILLIAM PIERCE, AGNIESZKA KIELCZEWSKA, WENTAO CHEN, OLIVIER NOLAN-STEVAUX, DARREN L. BATES, LISA WINKEL, CHRISTOPH DAHLHOFF, TOBIAS RAUM, CLAUDIA BLUEMEL, JONAS KARL-JOSEF HONER
-
Patent number: 11447567Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human FLT3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: August 1, 2016Date of Patent: September 20, 2022Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Tobias Raum, Claudia Blümel, Franziska Bott, Christoph Dahlhoff, Patrick Hoffmann, Elisabeth Nahrwold, Jochen Pendzialek
-
Publication number: 20210309743Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: April 21, 2021Publication date: October 7, 2021Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
-
Publication number: 20210284748Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: October 29, 2020Publication date: September 16, 2021Inventors: Tobias Raum, Claudia Blümel, Wibke Deisting, Patrick Hoffmann, Ralf Lutterbüse, Elisabeth Nahrwold, Olivier Nolan-Stevaux, Marc Panzer
-
Patent number: 11028171Abstract: The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CDS on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: April 18, 2016Date of Patent: June 8, 2021Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Bertram Weiss, Ann-Lena Frisk, Ruprecht Zierz, Peter Kufer, Tobias Raum, Doris Rau, Jonas Anlahr, Ralf Lutterbüse, Lisa Nahrwold, Christoph Dahlhoff, Claudia Blümel, Patrick Hoffmann
-
Publication number: 20210130465Abstract: The present invention provides bispecific antibody constructs characterized by comprising a first domain binding to MUC17, a second domain binding to an extracellular epitope of the human and the Macaca CD3E chain and optionally a third domain, which is a specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.Type: ApplicationFiled: December 31, 2018Publication date: May 6, 2021Inventors: Tobias Raum, Tara Arvedson, Julie Bailis, Christoph Dahlhoff, Sandra Ross, Irwin Chen, Claudia Blümel, Elisabeth Nahrwold, Jochen Pendzialek, Joachim Wahl
-
Patent number: 10851170Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: August 1, 2016Date of Patent: December 1, 2020Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.Inventors: Tobias Raum, Claudia Blümel, Wibke Deisting, Patrick Hoffmann, Ralf Lutterbüse, Elisabeth Nahrwold, Olivier Nolan-Stevaux, Marc Panzer
-
Publication number: 20200362039Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production.Type: ApplicationFiled: December 27, 2019Publication date: November 19, 2020Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Susanne Mangold, Ralf Lutterbüse, Patrick Hoffmann, Doris Rau, Matthias Klinger, Claudia Blümel
-
Publication number: 20200332002Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: May 6, 2020Publication date: October 22, 2020Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
-
Patent number: 10683351Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.Type: GrantFiled: March 4, 2019Date of Patent: June 16, 2020Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
-
Publication number: 20200055932Abstract: The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: August 2, 2019Publication date: February 20, 2020Inventors: Christoph Dahlhoff, Claudia Blümel, Johannes Brozy, Tobias Raum, Elisabeth Nahrwold, Tara Arvedson, Irwin Chen, Sandra Ross, Julie Bailis
-
Publication number: 20190263907Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: March 4, 2019Publication date: August 29, 2019Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
-
Patent number: 10294300Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: August 1, 2016Date of Patent: May 21, 2019Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek